Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

APPLIED THERAPEUTICS DEADLINE FOR LEADERSHIP is February 18, 2025 in a Securities Fraud Lawsuit - Contact Kaplan Fox & Kilsheimer LLP

By: TheNewswire.com
<div><p align="justify">NEW YORK - (<a href="https://www.newmediawire.com">NewMediaWire</a>) - December 24, 2024 - <a href="https://www.kaplanfox.com/?utm_source=NMW&amp;utm_medium=Press+Release&amp;utm_campaign=Applied+Therapeutics&amp;utm_id=Applied+Therapeutics&amp;utm_term=APLT+NMW">Kaplan Fox &amp; Kilsheimer LLP</a> announces that a class action lawsuit has been filed against Applied Therapeutics, Inc. (&ldquo;Applied Therapeutics&rdquo; or the &ldquo;Company&rdquo;) (NASDAQ: APLT) on behalf of investors that purchased or otherwise acquired Applied Therapeutics securities between January 3, 2024 and December 2, 2024 (the &ldquo;Class Period&rdquo;).</p> <p align="center"><a href="https://www.kaplanfox.com/case/applied-therapeutics-inc/?utm_source=NMW&amp;utm_medium=Press+Release&amp;utm_campaign=Applied+Therapeutics&amp;utm_id=Applied+Therapeutics&amp;utm_term=APLT+NMW">CLICK HERE TO JOIN THE CASE</a></p> <figure align="left" style="width: 240px; max-width: 100%; margin-bottom: 20px; float: left; margin-right: 20px;"><img src="http://newmediawire.s3.amazonaws.com/6769c72dda846f3dd21a4a79_1" alt="" width="240" style="width: 240px; max-width: 100%; height: auto;" /></figure> <p align="justify"><b>If you are an investor in Applied Therapeutics and have suffered losses, you may </b><a href="https://www.kaplanfox.com/case/applied-therapeutics-inc/?utm_source=NMW&amp;utm_medium=Press+Release&amp;utm_campaign=Applied+Therapeutics&amp;utm_id=Applied+Therapeutics&amp;utm_term=APLT+NMW"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:jcampisi@kaplanfox.com"><b>jcampisi@kaplanfox.com</b></a><b> or by calling (212) 329-8571.</b></p> <p align="justify"><b>DEADLINE REMINDER: </b>If you are a member of the proposed Class, you may move the court <b><u>no later than February 18, 2025</u></b> to serve as a lead plaintiff for the purported class.&nbsp; If you have losses we encourage you to contact us to learn more about the lead plaintiff process.&nbsp; You need not seek to become a lead plaintiff in order to share in any possible recovery.</p> <p align="justify">According to the complaint, on November 27, 2024, the Company disclosed that the U.S. Food and Drug Administration (&ldquo;FDA&rdquo;) issued a Complete Response Letter (&ldquo;CRL&rdquo;) for its new drug application for govorestat, AT-007-1002, for treatment of classic galactosemia (the &ldquo;NDA&rdquo;).&nbsp; The Company&rsquo;s press release states that the &ldquo;CRL indicate[d] that the FDA completed its review of the application and determined that it is unable to approve the NDA in its current form, citing deficiencies in the clinical application.&rdquo;</p> <p align="justify">Following this news, on November 29, 2024, Applied Therapeutics stock fell $6.54 per share, over 76%, to close at $2.03 per share on heavy trading volume.</p> <p align="justify">Then, on December 2, 2024 after the markets closed, the Company disclosed in a Form 8-K filing that following issuance of the CRL, the Company received a &ldquo;warning letter&rdquo; limited to the AT-007-1002 study and that the &ldquo;warning letter&rdquo; identified issues relating to &ldquo;electronic data capture&rdquo; and a &ldquo;dosing error in the dose-escalation phase of the study resulting in slightly lower levels than targeted in a limited number of patients, which was remedied prior to achieving maintenance dosing.&rdquo;&nbsp; According to the complaint, Applied Therapeutics&rsquo; stock price declined from a closing market price of $1.75 per share on December 2, 2024 to close at $1.29 per share on December 5, 2024.</p> <p align="justify"><b>WHY CONTACT KAPLAN FOX - </b>Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey.&nbsp; With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand.&nbsp; Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients.&nbsp; For more information about Kaplan Fox &amp; Kilsheimer LLP, you may visit our website at <a href="http://www.kaplanfox.com">www.kaplanfox.com</a>.</p> <p align="justify">This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.</p> <p align="justify">If you have any questions about this Notice, your rights, or your interests, please contact:</p> <p><b>CONTACT:</b><br />Jeffrey P. Campisi<br /><a href="http://www.kaplanfox.com/">KAPLAN FOX &amp; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York&nbsp;10022<br />(212) 329-8571<br /><a href="mailto:jcampisi@kaplanfox.com">jcampisi@kaplanfox.com</a></p> <p>Laurence D. King<br /><a href="http://www.kaplanfox.com/">KAPLAN FOX &amp; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1560<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p><p class="nmw_link">View the original release on <a href="https://www.newmediawire.com/nmw_release/?rid=6769c72dda846f3dd21a4a79/applied-therapeutics-deadline-for-leadership-is-february-18-2025-in-a-securities-fraud-lawsuit-contact-kaplan-fox-kilsheimer-llp">www.newmediawire.com</a></p></div>
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.